These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 17472825

  • 1. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
    Makus KG, McCormick J.
    Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
    [Abstract] [Full Text] [Related]

  • 2. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F, Duh MS, Gosselin A, Paradis PE.
    Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
    [Abstract] [Full Text] [Related]

  • 3. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
    LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O.
    Neurology; 2008 May 27; 70(22 Pt 2):2179-86. PubMed ID: 18505997
    [Abstract] [Full Text] [Related]

  • 4. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC, Le L, Ramsey SD, Solow BK, Zakharyan A, Stockl KM, Harada AS, Curtis B.
    Epilepsia; 2011 Jul 27; 52(7):1365-71. PubMed ID: 21692778
    [Abstract] [Full Text] [Related]

  • 5. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C, Ashton T, Davis P.
    Appl Health Econ Health Policy; 2014 Oct 27; 12(5):537-46. PubMed ID: 25005492
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
    Berg M, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, Dworetzky BA, Pollard JR, Elder EJ, Jiang W, Jiang X, Switzer RD, Privitera MD.
    JAMA Neurol; 2017 Aug 01; 74(8):919-926. PubMed ID: 28654954
    [Abstract] [Full Text] [Related]

  • 11. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, Polli JE.
    Epilepsia; 2015 Sep 01; 56(9):1415-24. PubMed ID: 26201987
    [Abstract] [Full Text] [Related]

  • 12. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
    Privitera MD, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, Dworetzky BA, Pollard JR, Elder EJ, Jiang W, Jiang X, Berg M.
    Lancet Neurol; 2016 Apr 01; 15(4):365-72. PubMed ID: 26875743
    [Abstract] [Full Text] [Related]

  • 13. Current approaches to the use of generic antiepileptic drugs.
    Krämer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, Josephs D, van Rijckevorsel K, Zaccara G.
    Epilepsy Behav; 2007 Aug 01; 11(1):46-52. PubMed ID: 17537678
    [Abstract] [Full Text] [Related]

  • 14. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA.
    Pediatrics; 2006 Aug 01; 118(2):e371-8. PubMed ID: 16847080
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
    Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Crémieux PY.
    Dis Manag; 2007 Aug 01; 10(4):216-25. PubMed ID: 17718660
    [Abstract] [Full Text] [Related]

  • 17. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs.
    Bautista RE, Gonzales W, Jain D.
    Epilepsy Res; 2011 Jun 01; 95(1-2):158-67. PubMed ID: 21530177
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.